anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants randomly assigned to this condition will complete a resistance training program consisting of three weekly hour-long full body exercise sessions. Participants will be supported by a personal trainer for six exercise session during their first month of training and will complete the remaining six sessions during this month independently. Participants will then continue to exercise independently following this first month of intervention. Participants will fill out weekly self-report measures (\~20 minutes each time) via the internet during their first four weeks of study participation and at 1-week, 1-month, and 3-months (\~20 minutes each time) follow-up after they have completed the supervised portion of this study.
PROBLEM TO BE SOLVED: To obtain a hypotensive agent that has the hypotensive action and is particularly useful as an antihypertensive drug for the hypertensive patients with high concentration of catecholamine in blood by using a specific S-adenosyl- L-methionine derivative as an active ingredient. SOLUTION: The objective hypotensive agent includes, as an active ingredient, S-adenosyl-L-methionine derivative represented by the formula [R is a (substituted) 5'-deoxyadenosxn-5'-yl; n is 1-6] or the pharmacologically acceptable salts. This compound can be used directly, as it is, or in the forms of a variety of pharmaceutical preparations. When it is used in oral preparation compositions, a proper pharmacologically acceptable carrier may be used. In a preparation suitable for parenteral administration, it preferably comprises a sterilized water-based preparation including the active compound that is adjusted the surface tension to that equal to the blood of the patient. This compound can be orally or parenterally as an injection solution or the like in the pharmaceutical preparation and the effective dose and the administration time is properly 60-1,200 mg/60 kg body weight/day.
<P>PROBLEM TO BE SOLVED: To enable anyone to easily and promptly record an electronic medical chart.  <P>SOLUTION: A pen type input device (e.g. a liquid crystal pen tablet) is adopted to a hospital computer in creation of the electronic medical chart. Templates for sketching various affected areas are preregistered in the hospital computer. A doctor touches entered affected area figure display areas 27a, 27b of an affected area figure sheet 27 twice with a pen in the case of sketching the affected area figure and sketches the affected areas with a liquid crystal pen using the entered affected area figure or the forms for sketching as design. The doctor performs DO input by displaying a DO input sheet 100 by touching a desired display column of a medical examination act sheet 25 twice with the pen, or touching a DO input button 13 with the pen and touching check boxes of the medical examination act developed in the DO input sheet with the pen in performing the DO input.  <P>COPYRIGHT: (C)2007,JPO&INPIT
PURPOSE:To obtain a laxative composition, composed of a gum and enteric substance derived from a plant of the genus Plantago without choking, becoming sticky or sticking in the mouth in direct administration thereof and any feeling of full stomach even in the administration due to no swelling in the stomach. CONSTITUTION:A laxative composition composed of a gum, e.g. a polysaccharide, derived from a plant (e.g. Plantago ovata) of the genus Plantago, and an enteric substance, e.g. hydroxypropyl methyl cellulose or methacrylic acid- methyl methacrylate copolymer. The aforementioned laxative composition is prepared by a coating of kneading method and coating a core substance containing 20-95wt.% gum with a coating solution containing the enteric substance so as to provide 5-40wt.% amount of the enteric substance in the film layer or kneading the gum in an amount of 20-95wt.% based on the total weight with the enteric substance in an amount of 10-30wt.% based on the gum.
PURPOSE: In the early stages of the COVID-19 pandemic, preliminary results that later proved to be incorrect suggested the possible efficacy of anti-infective drugs such as azithromycin for the treatment of SARS-CoV-2 infection. These preliminary data may have influenced the prescription of azithromycin. However, no individual-level data linking the use of this antibiotic to acute SARS-CoV-2 infection are available. The present analysis aims to fill this gap.
METHODS: A retrospective population-based cohort design was used including patients diagnosed with SARS-CoV-2 infection in the period ranging from February 2020 to February 2022. The data source for antibiotic consumption was the drug database of outpatient prescriptions of Emilia-Romagna Region (Italy). Antibiotics were classified according to the Anatomical Therapeutic Chemical (ATC) classification system. Consumption rates and percentages of azithromycin DDDs (defined daily doses) during the acute phase of the infection were compared with a previous control period and with the post-acute phase. Analyses were stratified by four groups according to the prevalent virus variant at time of diagnosis.
RESULTS: Comparing the previous control period with the acute phase of infections, the rates of azithromycin consumption (DDD per 1000 individuals per day) increased from 1.17 to 23.11, from 0.80 to 33.03, from 0.81 to 21.01, and from 1.02 to 9.76, in the pre-Alpha, Alpha, Delta, and Omicron periods, respectively. Similarly, the percentages of individuals receiving azithromycin, and the azithromycin DDDs percentages over total systemic antibiotics DDDs increased in acute phases of infection compared with control periods. The consumption rates and percentages returned to preinfection levels in the post-acute phase. In the study period, 12.9% of the use of azithromycin in the entire adult population of Emilia-Romagna was attributable to acute SARS-CoV-2 infection.
CONCLUSIONS: Considering the low likelihood of bacterial coinfections, the increased azithromycin consumption in the acute phase of SARS-CoV-2 infection suggests inappropriate prescribing of this antibiotic.
A method for administering biological agents to eggs is disclosed which comprises providing the agents in a particulate carrier and injecting the carrier into the air cells of the eggs. The egg is preferably maintained in a vertical position with the air cell on top to facilitate migration of the particulate carrier between the inner and outer membranes which define the air cell, to the lower end of the egg. The particulate carrier releases the biological agent to the surrounding fluid and blood vessels. In addition, the carrier is embodied in the bird upon hatching from the egg, and therefore is available to continue to release the biological agent to the bird posthatch. 
     Also disclosed is a composition of polyester microparticles containing bioactive polypeptide agents and methods for preparing the composition and administering bioactive agents. The composition comprises biocompatible, biodegradable microparticles having a polyester matrix and from about 5% to about 25% by weight of a biologically active, water-soluble polypeptide dispersed throughout the matrix, the polypeptide selected fom the group consisting of growth hormone releasing factor, synthetic analogs of growth hormone releasing factor, and pharmacologically active fragments thereof. The method for preparing the composition includes dissolving polyester in an organic solvent; suspending a biologically active agent in the polyester solution; emulsifying the suspension into an aqueous medium in which the agent is insoluble and evaporating the solvent from the emulsion to produce microparticles. The method for administering a bioactive agent to an organism involves suspending the microparticles in a suitable liquid and injecting the organism.
INTRODUCTION: Total knee arthroplasty (TKA) is accompanied by severe postoperative pain, which is reported to be an important cause of chronic pain. Ultrasound-guided adductor canal block (ACB) combined with infiltration between the popliteal artery and posterior capsular of the knee (IPACK) has been proven to have a better effect on relieving acute pain after TKA. However, whether it has a significant effect on the incidence of chronic pain after TKA has not been reported. This trial was designed to investigate the effect of ultrasound-guided ACB combined with IPACK on the incidence and intensity of chronic pain after TKA.
METHODS: In this prospective, randomized, double-blind, placebo-controlled study, 100 subjects scheduled for TKA were randomly (1:1) divided into two groups: the ropivacaine group and the placebo group. Patients in each group received ultrasound-guided ACB + IPACK procedures with 0.25% ropivacaine or equal volume normal saline. All patients received multimodal analgesia. Pain intensity was assessed using the Numerical Rating Scale (NRS). The primary outcome was the incidence of chronic pain at 3 months after TKA by telephone follow-up. In addition, pain intensity in early resting and mobilized states, chronic pain intensity, the time to first rescue analgesia; opioid consumption; CRP and IL-6 after the operation; length of postoperative hospital stay; and cost of hospitalization and postoperative complications; as well as the function of the knee in the early stage after the operation, were recorded.
RESULTS: Ninety-one participants were included in the final analysis. At 3 months, the incidence of chronic pain was 30.4% in the ropivacaine group, significantly lower than 51.1% in the placebo group. Compared with the placebo group, the ACB + IPACK with ropivacaine group had significantly lower pain scores at 4 hours, 8 hours, 16 hours, and 24 hours after the operation; increased the knee range of motion at 8 hours and 24 hours after the operation; and a significantly decreased incidence of chronic pain at 3 months after the operation. During the follow-up period, there were no nerve block-related complications in either group.
CONCLUSION: In the context of multimodal analgesia protocols, ACB combined with IPACK before surgery decreases the incidence and intensity of chronic pain 3 months after TKA compared with placebo injection. In addition, it reduces the NRS scores, whether at rest or during mobilization, and improves knee function within 24 hours after TKA.
TRIAL REGISTRATION: This trial was registered in the China Clinical Trial Center (registration number ChiCTR2200065300) on November 1, 2022.
BACKGROUND: Systemic sclerosis (SSc) is a heterogeneous disease, characterized by variable tissue and vascular fibrosis in the context of autoimmune activation. CCL24 (or Eotaxin2) has been shown to promote microangiopathic, proinflammatory, and profibrotic processes in preclinical models of SSc. Here, we study serum CCL24 levels in a real-life cohort of patients with SSc, to determine its distribution across disease features and its value in predicting disease progression and related mortality.
METHODS: Serum CCL24 was assessed in an observational cohort of consecutively enrolled patients with SSc. A high CCL24 cutoff was defined based on its distribution in a matched cohort of healthy controls. Disease progression and mortality were analyzed from the date of serum assessment.
RESULTS: Two-hundred thirteen consecutively enrolled patients with SSc were included in this analysis. Median disease duration was six years (interquartile range 3-14), 28.6% of patients presented with interstitial lung disease (ILD), 46.9% had digital ulcers, and 25.3% showed high CCL24 serum concentration. High-CCL24 patients were more frequently male and positive for anti-scl-70, with a diagnosis of ILD and synovitis (P < 0.05 for all). Notably, high-CCL24 patients had lower diffusion of carbon monoxide and higher prevalence of digital ulcers, telangiectasias, and calcinosis (P < 0.05 for all). In a longitudinal setting, high CCL24 was associated with greater lung function decline and with higher disease-related mortality.
CONCLUSION: Serum CCL24 is a biomarker of disease severity across fibrotic and vascular disease manifestations. These data support the development of therapies targeting CCL24 as a novel comprehensive therapeutic target in SSc.
PROBLEM TO BE SOLVED: To obtain an activity accelerator suitable for curing and prevention of hyperlipemia disease. SOLUTION: This accelerator is composed of essence of a plant body belonging to genus Paeonia in family Paeoniaceae (preferably Paeonia suffruticosa). Preferably, a using position of the plant body is a velamen part. The essence is preferably, e.g. an extract from a polar solvent or its distilled out substance from the solvent. Further, an optimum essence is preferably obtained by extracting the velamen part of the plant of genus Paeonia in family Paeoniaceae with hot water, adsorbing the extract on a suitable carrier, eluting with ethanol or a mixed solution of ethanol with water and condensing under a reduced pressure. A suitable administration dose of the essence obtained by such a process is 5-500mg for an adult per 1 day in dividing to several times in a case of oral administration or 1-100mg in a case of an injection.  Otherwise, an administration as a food or a medicinal composition is also possible.
OBJECTIVES: Prolonged pleural effusion/chylothorax (PPE/C) is a less investigated complication following paediatric cardiac surgery, and its true incidence, risk factors and impact on postoperative outcomes are not well described. We aim to address these gaps in knowledge using data from a prospective, multicentre study.
METHODS: Data on 9 post-operative morbidities (unplanned reinterventions, extracorporeal life support, necrotising enterocolitis, PPE/C, renal replacement therapy, major adverse events, acute neurological events, feeding issues and postsurgical infection) were prospectively collected at 5 UK centres between 2015 and 2017, following paediatric cardiac surgery. Incidence of PPE/C, associations with procedure types, and risk factors were described. Mortality (30-day and 6-month) and hospital length of stay (HLoS) were compared between those with isolated PPE/C, single non-PPE/C morbidity, no morbidity, multimorbidity PPE/C and non-PPE/C multimorbidity.
RESULTS: A total of 3090 procedures (2861 patients) were included (median age, 228 days). There were 202 PPE/C (incidence of 6.5%), occurring at a median of 6 days postoperatively (interquartile range: 3-10). PPE/C was associated with excess early mortality only when complicating scenarios where at least 2 other post-operative morbidities occurred. On average PPE/C is associated with 8 more HLoS days, but the relative impact is greatest when comparing isolated PPE/C with no morbidity (P < 0.001), whereas in multimorbidity scenarios, PPE/C does not significantly contribute to an increase of HLoS.
CONCLUSIONS: Addition of PPE/C increases mortality but not HLoS in multimorbidity and HLoS only in single morbidity scenarios. This reinforces the important role of prevention, early detection and management of PPE/C in complex situations.
PURPOSE:To obtain the titled cosmetic having excellent emulsified state in acidic region, high age stability and high safety to skin, by compounding an N<alpha>,N<alpha>-dimethyl-N<epsilon>-long-chain acyllysine as an emulsifier. CONSTITUTION:The titled cosmetic contains 0.01-10.0wt% compound of formula (R is 16-22C acyl). The compound of formula may be used singly or in combination or other surfactant may be used as an emulsifying assistant. The above cosmetic may be compounded properly with conventional humectant, ultraviolet absorber, alcohol, preservative, thickener, pigment, perfume, etc. Any oil-phase component used in conventional cosmetics may be used in the present cosmetic. The compound of formula may be added to the oil phase or the aqueous phase in the production of the above cosmetic.
Apply Catapres‑TTS® (clonidine transdermal system) once every 7 days to a hairless area of intact skin on the upper outer arm or chest. Each new application of Catapres‑TTS® should be on a different skin site from the previous location. If the system loosens during 7‑day wearing, the adhesive cover should be applied directly over the system to ensure good adhesion. There have been rare reports of the need for patch changes prior to 7 days to maintain blood pressure control.

To initiate therapy, Catapres‑TTS® dosage should be titrated according to individual therapeutic requirements, starting with Catapres‑TTS®-1. If after one or two weeks the desired reduction in blood pressure is not achieved, increase the dosage by adding another Catapres‑TTS®-1 or changing to a larger system. An increase in dosage above two Catapres‑TTS®-3 is usually not associated with additional efficacy.

When substituting Catapres‑TTS® for oral clonidine or for other antihypertensive drugs, physicians should be aware that the antihypertensive effect of Catapres‑TTS® may not commence until 2‑3 days after initial application. Therefore, gradual reduction of prior drug dosage is advised. Some or all previous antihypertensive treatment may have to be continued, particularly in patients with more severe forms of hypertension.
PURPOSE:To obtain the subject new compound, having a woody or an ambery aroma and flavor characteristics, excellent in persistence of the characteristics and useful for foods such as beverages or favorite foods or as a compounding material for cosmetics such as a cosmetic base. CONSTITUTION:The optically active 13-alkoxy-8alpha, 13- epoxy-14,15,16-trinorlabdanes of formula I (R is a 1-4C alkyl; the wavy line indicates that the compounds are the cis- or trans-isomer), e.g. 13-methoxy-8alpha,13- epoxy-14,15,16-trinorlabdane. The compounds of formula I are readily obtained by reacting a compound of formula II with a compound of the formula ROH (preferably a lower alcohol) in the presence of an acidic catalyst. Furthermore, the reaction is preferably carried out at a reactional temperature within the range of about 0-20 deg.C for about 0.1-2hr. The alcohol of the formula ROH is preferably used in an amount of about 1.2-2 mol based on 1mol compound of formula II.
Intellectual disability and neurobehavioural comorbidities affect at least 50% of the individuals with Duchenne muscular dystrophy (DMD), which, although a rare genetic disease, is the most common form of muscular dystrophy in childhood. Several studies have documented that 25% of the DMD population has intellectual disability with recent studies suggesting that autism and clinically relevant hyperactivity affects 20% and 25% of DMD boys respectively. A milder allelic variant, named Becker muscular dystrophy (BMD), has similar prevalence in the population and is also associated with variable degrees of central nervous system (CNS) comorbidities, which however have been less well defined.

The investigators will address these deficiencies in a large multicentre study funded by the European Commission (EU H2020) involving 6 countries (Denmark; The Netherlands; France; Spain; Italy and UK) with the largest European neuromuscular centres and advocacy groups. The aim will be to study the neurobehavioural aspects of DMD and BMD as well as their correlation to the genotype. This study will involve male participants with DMD aged 5-17 years and with BMD aged 5-50 years. It will comprise of online questionnaires that will be completed either by a parent of a participant \<17 years or an adult participant. The questionnaires take approximately 70 minutes to complete, however this can be done in multiple sittings. Currently there is a lack of information to assist the prognosis of CNS comorbidities, as existing databases and registries typically focus on the motor milestones and physical disability of these patients. There is therefore, an urgent need to present the course and outcomes in DMD and BMD patients with a wide range of DMD mutations, to provide information at the point of diagnosis and onwards for families, clinicians and service providers. It will also assist in paving the way to greater biological understanding and personalization of interventions.
<P>PROBLEM TO BE SOLVED: To provide a manufacturing process for orally disintegrating tablets which can stand up to the a system in which after shipped, the tablets are packed in one pack (packed for one dosage) with an automatic tablet packing machine and delivered to the patients at medical institutions.  <P>SOLUTION: The manufacturing process comprises a step in which the powdery mixture of (a) the main excipient component selected from water-soluble saccharides, saccharide alcohols or their mixture and (b) a pharmaceutical additive composed of a water-insoluble low moisture-absorbing polymer is granulated using (c) an aqueous dispersion containing a water-insoluble hydrophilic pharmaceutical additive and a step in which the granules obtained are mixed at least with a lubricant and compressed. In the process, (d) medicinal components are added to the main excipient component and/or the aqueous dispersion. Thus, the orally disintegrating tablets whose degree of lowering of the hardness, when exposed to the atmosphere in an unpacked state is in an acceptable range are obtained. Components (b) may be added to the aqueous dispersion containing component (c) or to the granules together with the lubricant on tableting, in the stead of mixing it with the main excipient component.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
A compound represented by the following formula (I): (I) [wherein X1 represents oxygen, etc.; X2 represents oxygen, etc.; R1 represents an alkylsulfonyl or another group on the ring A; R2 represents, e.g., C3-7 cyclic alkyl optionally substituted by halogeno, etc.; R3 represents a substituent on the ring B, e.g., lower alkyl; the formula (II) [Chemical formula 1] (II) represents 6- to 10-membered aryl, etc.; and the formula (III) [Chemical formula 1] (III) represents a mono- or bicyclic heteroaryl which optionally has a substituent represented by the R3 in the ring B and in which the carbon atom bonded to the nitrogen atom of the amide group in the formula (I) forms C=N in cooperation with the nitrogen atom of the ring] or a pharmaceutically acceptable salt of the compound. The compound and salt function to activate glucokinase and are useful as a therapeutic agent for diabetes.
PROBLEM TO BE SOLVED: To obtain the subject composition capable of effectively and easily masking an unpalatable taste such as bitter, acidic or astringent taste to correct the taste by adding a taste-remedial agent to a component having the unpalatable taste, applying shear forces to the mixture and then granulating the product in a dry state. SOLUTION: This granular composition whose unpalatable taste is masked is obtained by applying shear forces to a mixture of (A) a component having an unpalatable taste with (B) a taste remedial agent and then granulating the obtained particles (preferably in a dry state). The composition is preferably further mixed with (C) a wax component. The composition may be obtained by a method comprising adding the component C to the mixture of the components A and B, applying shear forces to the mixture and then granulating the product in a dry state or a method comprising applying shear forces to the mixture of the components A and B, granulating the product in a dry state, and then adding and mixing the component C with the granules. Thereby, the excellent masking effect is obtained, and the good control in the change of the corrected taste with the passage of time can be expected.  Even when the amount of the wax component is reduced, the effect can sufficiently be exhibited.
Patients received one plasma volume plasma exchanges with 5% albumin replacement fluid. Five plasma exchange procedures occurred every second day with breaks over the weekend allowed. Patients treated in the apheresis units at the University Health Network.